Best Rising Stocks To Own For 2016

Best Rising Stocks To Own For 2016: Zoetis Inc (ZTS)

Zoetis Inc, incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The primary livestock species are cattle (both beef and dairy), swine, poultry, sheep and fish, and the primary companion animal species are dogs, cats and horses. In February 2014, Benchmark Holdings PLC purchased aquaculture vaccine and development assets from animal health company Zoetis Inc.

The Company's more than 300 product lines include vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceutical products. The Company's product portfolio also includes businesses, such as diagnostics, genetics, devices and services, such as dairy data management, e-learning and professional consulting. The Company operates in North America, Europe, Africa, Asia, Australia and Latin America.

Advisors' Opinion:

• [By Johanna Bennett]

  Bill Ackman is going to the dogs, not to mention the cats and cows.

  Shares of Zoetis (ZTS) closed at $43.72, rising 8.86% after the Wall Street Journal reported that the hedge fund titan had taken a $2 billion stake in the animal-health company and could push Zoetis to sell itself to a large drug maker.

  Zoetis was spun off by Pfizer (PFE) in last year.

  As the WSJ reports:

  Ackman's Pershing Square Capital Management LP has built the stake, which amounts to roughly 10% of Zoetis, with fellow hedge fund Sachem Head Capital Management LP, the people said. Sachem Head is run by Scott Ferguson, a former protégé of Mr. Ackman.

  A spokesman for Florham Park, N.J.-based Zoetis, which has a market value of about $20 billion, said the company got a call from Mr. Ackman regarding the investment, but declined to comment on it.

  Zoetis makes vaccines and medications for livestock and house hold pets, generating $4.6 billion in sales last year. It is the largest player in the animal-health industry.

  Citing unnamed sources, the WSJ reports that Ackman could be setting up Zoetis as a "a fallback plan" for Valeant Pharmaceuticals (VRX) if it fails to buy Allergan (AGN)

  The WSJ reports:

  The animal-health industry has been an active participant in the recent mergers-and-acquisitions boom. In April, Novartis AG agreed to sell its animal-health unit to Eli Lilly & Co. for $5.4 billion. The deal is expected to boost Lilly's position in the industry to No. 2 behind Zoetis.

  Valeant Chief Executive Michael Pearson has said he has ambitions of tripling his company's size through acquisitions, and has indicated animal health is an area of potential interest.

   

• [By Benjamin Shepherd]

  "Man's best friend" could turn out to be one of your best investments, too. The numbers tell the story: Pet care is a high-growth industry.
  
  More than 60 percent of US households report an animal in residence. About 46 million US families own at least one dog, with 40 million reporting that they own cats. Not only are dogs and cats good company, but years of research show that pets convey health benefits, with owners reporting lower blood pressure, less anxiety and higher immunity to illness
  
  But pets aren't cheap. Aside from the obvious cost of purchasing the animals they also need to eat, play and have their own health issues addressed, costing Americans an estimated $55.53 billion last year. That price tag has been steadily rising for more than a decade, as an ever-growing number of households call at least one animal "family."

• [By Jake L'Ecuyer]

  Zoetis (NYSE: ZTS) was down as well, falling 5.25 percent to $29.50 percent after the company guided its fiscal year 2014 revenue and EPS below street estimates.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-rising-stocks-to-own-for-2016.html